Investor Relations

Overview

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. Our first commercial product, Jakafi® (ruxolitinib), is approved in the United States for patients with intermediate or high-risk myelofibrosis and for patients with polycythemia vera who have had an inadequate response to or are intolerant to hydroxyurea. We have a diverse and growing portfolio of product candidates, including both small and large molecules.

Events & Presentations

Upcoming
More events are coming soon.
Prior

February 14, 2019 8:00 AM EST
Q4 2018 Incyte Corporation Earnings Conference Call

January 07, 2019 2:00 PM PST
J. P. Morgan 37th Annual Healthcare Conference Q/A Session

January 07, 2019 1:30 PM PST
J. P. Morgan 37th Annual Healthcare Conference Presentation

SEC Filings

Filing date Description Filing Group View

Report of unscheduled material events or corporate event

Current Reports

S-3ASR

Registration Statements

Annual report which provides a comprehensive overview of the company for the past year

Annual Filings

Investor Contacts

Michael Booth D.Phil
Vice President, Investor Relations
Phone: 302.498.5914
E-mail: mbooth@incyte.com

Lauren Kwiecinski
Senior Director, Investor Relations
Phone: 302.498.6141
E-mail: lkwiecinski@incyte.com

Computershare
P.O. Box 43078
Providence, RI 02940-3078 Phone: 877.272.1536